Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke.

Balasubramanian V, Domanskyi A, Renko JM, Sarparanta M, Wang CF, Correia A, Mäkilä E, Alanen OS, Salonen J, Airaksinen AJ, Tuominen R, Hirvonen J, Airavaara M, Santos HA.

Biomaterials. 2020 Jan;227:119556. doi: 10.1016/j.biomaterials.2019.119556. Epub 2019 Oct 18.

2.

Neuronal Activation Stimulates Cytomegalovirus Promoter-Driven Transgene Expression.

Bäck S, Dossat A, Parkkinen I, Koivula P, Airavaara M, Richie CT, Chen YH, Wang Y, Harvey BK.

Mol Ther Methods Clin Dev. 2019 Jul 3;14:180-188. doi: 10.1016/j.omtm.2019.06.006. eCollection 2019 Sep 13.

3.

Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra.

Albert K, Renko JM, Mätlik K, Airavaara M, Voutilainen MH.

Front Neurosci. 2019 Jun 11;13:590. doi: 10.3389/fnins.2019.00590. eCollection 2019.

4.

Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury.

Pöyhönen S, Er S, Domanskyi A, Airavaara M.

Front Physiol. 2019 Apr 26;10:486. doi: 10.3389/fphys.2019.00486. eCollection 2019. Review.

7.

Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats.

Bäck S, Necarsulmer J, Whitaker LR, Coke LM, Koivula P, Heathward EJ, Fortuno LV, Zhang Y, Yeh CG, Baldwin HA, Spencer MD, Mejias-Aponte CA, Pickel J, Hoffman AF, Spivak CE, Lupica CR, Underhill SM, Amara SG, Domanskyi A, Anttila JE, Airavaara M, Hope BT, Hamra FK, Richie CT, Harvey BK.

Neuron. 2019 Apr 3;102(1):105-119.e8. doi: 10.1016/j.neuron.2019.01.035. Epub 2019 Feb 18.

PMID:
30792150
8.

Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.

Albert K, Voutilainen MH, Domanskyi A, Piepponen TP, Ahola S, Tuominen RK, Richie C, Harvey BK, Airavaara M.

J Neurosci Res. 2019 Mar;97(3):346-361. doi: 10.1002/jnr.24363. Epub 2018 Dec 12.

PMID:
30548446
9.

Implementation of deep neural networks to count dopamine neurons in substantia nigra.

Penttinen AM, Parkkinen I, Blom S, Kopra J, Andressoo JO, Pitkänen K, Voutilainen MH, Saarma M, Airavaara M.

Eur J Neurosci. 2018 Sep;48(6):2354-2361. doi: 10.1111/ejn.14129. Epub 2018 Sep 20.

10.

Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease.

Penttinen AM, Parkkinen I, Voutilainen MH, Koskela M, Bäck S, Their A, Richie CT, Domanskyi A, Harvey BK, Tuominen RK, Nevalaita L, Saarma M, Airavaara M.

Front Neurol. 2018 Jun 20;9:457. doi: 10.3389/fneur.2018.00457. eCollection 2018.

11.

Poststroke delivery of MANF promotes functional recovery in rats.

Mätlik K, Anttila JE, Kuan-Yin T, Smolander OP, Pakarinen E, Lehtonen L, Abo-Ramadan U, Lindholm P, Zheng C, Harvey B, Arumäe U, Lindahl M, Airavaara M.

Sci Adv. 2018 May 23;4(5):eaap8957. doi: 10.1126/sciadv.aap8957. eCollection 2018 May.

12.

Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury.

Anttila JE, Albert K, Wires ES, Mätlik K, Loram LC, Watkins LR, Rice KC, Wang Y, Harvey BK, Airavaara M.

eNeuro. 2018 Apr 18;5(2). pii: ENEURO.0395-17.2018. doi: 10.1523/ENEURO.0395-17.2018. eCollection 2018 Mar-Apr.

13.

Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors.

Ahonen TJ, Rinne M, Grutschreiber P, Mätlik K, Airavaara M, Schaarschmidt D, Lang H, Reiss D, Xhaard H, Gaveriaux-Ruff C, Yli-Kauhaluoma J, Moreira VM.

Eur J Med Chem. 2018 May 10;151:495-507. doi: 10.1016/j.ejmech.2018.02.074. Epub 2018 Mar 26.

PMID:
29649744
14.

Towards developing a model to study alcohol drinking and craving in female mice housed in automated cages.

Koskela M, Piepponen TP, Andressoo JO, Võikar V, Airavaara M.

Behav Brain Res. 2018 Oct 15;352:116-124. doi: 10.1016/j.bbr.2018.03.027. Epub 2018 Mar 20.

PMID:
29572104
15.

The κ-opioid receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats.

Uhari-Väänänen J, Raasmaja A, Bäckström P, Oinio V, Carroll FI, Airavaara M, Kiianmaa K, Piepponen P.

Psychopharmacology (Berl). 2018 May;235(5):1581-1591. doi: 10.1007/s00213-018-4868-x. Epub 2018 Feb 28.

PMID:
29492614
16.

Differential Spinal and Supraspinal Activation of Glia in a Rat Model of Morphine Tolerance.

Jokinen V, Sidorova Y, Viisanen H, Suleymanova I, Tiilikainen H, Li Z, Lilius TO, Mätlik K, Anttila JE, Airavaara M, Tian L, Rauhala PV, Kalso EA.

Neuroscience. 2018 Apr 1;375:10-24. doi: 10.1016/j.neuroscience.2018.01.048. Epub 2018 Feb 6.

PMID:
29421434
17.

Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.

Huotarinen A, Penttinen AM, Bäck S, Voutilainen MH, Julku U, Piepponen TP, Männistö PT, Saarma M, Tuominen R, Laakso A, Airavaara M.

Neuroscience. 2018 Mar 15;374:250-263. doi: 10.1016/j.neuroscience.2018.01.052. Epub 2018 Feb 3.

18.

Development and plasticity of meningeal lymphatic vessels.

Antila S, Karaman S, Nurmi H, Airavaara M, Voutilainen MH, Mathivet T, Chilov D, Li Z, Koppinen T, Park JH, Fang S, Aspelund A, Saarma M, Eichmann A, Thomas JL, Alitalo K.

J Exp Med. 2017 Dec 4;214(12):3645-3667. doi: 10.1084/jem.20170391. Epub 2017 Nov 15.

19.

MANF Is Essential for Neurite Extension and Neuronal Migration in the Developing Cortex.

Tseng KY, Danilova T, Domanskyi A, Saarma M, Lindahl M, Airavaara M.

eNeuro. 2017 Sep 29;4(5). pii: ENEURO.0214-17.2017. doi: 10.1523/ENEURO.0214-17.2017. eCollection 2017 Sep-Oct.

20.

MANF Promotes Differentiation and Migration of Neural Progenitor Cells with Potential Neural Regenerative Effects in Stroke.

Tseng KY, Anttila JE, Khodosevich K, Tuominen RK, Lindahl M, Domanskyi A, Airavaara M.

Mol Ther. 2018 Jan 3;26(1):238-255. doi: 10.1016/j.ymthe.2017.09.019. Epub 2017 Sep 21.

21.

Multifunctional Nanotube-Mucoadhesive Poly(methyl vinyl ether-co-maleic acid)@Hydroxypropyl Methylcellulose Acetate Succinate Composite for Site-Specific Oral Drug Delivery.

Kerdsakundee N, Li W, Martins JP, Liu Z, Zhang F, Kemell M, Correia A, Ding Y, Airavaara M, Hirvonen J, Wiwattanapatapee R, Santos HA.

Adv Healthc Mater. 2017 Oct;6(20). doi: 10.1002/adhm.201700629. Epub 2017 Jul 17.

PMID:
28714596
22.

9-cis retinoic acid induces neurorepair in stroke brain.

Yu SJ, Airavaara M, Wu KJ, Harvey BK, Liu HS, Yang Y, Zacharek A, Chen J, Wang Y.

Sci Rep. 2017 Jul 3;7(1):4512. doi: 10.1038/s41598-017-04048-2.

23.

Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Savolainen MH, Albert K, Airavaara M, Myöhänen TT.

Exp Brain Res. 2017 Jul;235(7):2189-2202. doi: 10.1007/s00221-017-4962-z. Epub 2017 Apr 24.

PMID:
28439627
24.

Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra.

Mätlik K, Vihinen H, Bienemann A, Palgi J, Voutilainen MH, Booms S, Lindahl M, Jokitalo E, Saarma M, Huttunen HJ, Airavaara M, Arumäe U.

eNeuro. 2017 Feb 20;4(1). pii: ENEURO.0128-16.2017. doi: 10.1523/ENEURO.0128-16.2017. eCollection 2017 Jan-Feb.

25.

AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.

Albert K, Voutilainen MH, Domanskyi A, Airavaara M.

Genes (Basel). 2017 Feb 8;8(2). pii: E63. doi: 10.3390/genes8020063. Review.

26.

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.

Runeberg-Roos P, Piccinini E, Penttinen AM, Mätlik K, Heikkinen H, Kuure S, Bespalov MM, Peränen J, Garea-Rodríguez E, Fuchs E, Airavaara M, Kalkkinen N, Penn R, Saarma M.

Neurobiol Dis. 2016 Dec;96:335-345. doi: 10.1016/j.nbd.2016.07.008. Epub 2016 Jul 15.

PMID:
27425888
27.

Accumbal μ-Opioid Receptors Modulate Ethanol Intake in Alcohol-Preferring Alko Alcohol Rats.

Uhari-Väänänen J, Raasmaja A, Bäckström P, Oinio V, Airavaara M, Piepponen P, Kiianmaa K.

Alcohol Clin Exp Res. 2016 Oct;40(10):2114-2123. doi: 10.1111/acer.13176. Epub 2016 Aug 10.

PMID:
27508965
28.

Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors.

Anttila JE, Whitaker KW, Wires ES, Harvey BK, Airavaara M.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt A):3-14. doi: 10.1016/j.pnpbp.2016.07.003. Epub 2016 Jul 4. Review.

29.

Update of neurotrophic factors in neurobiology of addiction and future directions.

Koskela M, Bäck S, Võikar V, Richie CT, Domanskyi A, Harvey BK, Airavaara M.

Neurobiol Dis. 2017 Jan;97(Pt B):189-200. doi: 10.1016/j.nbd.2016.05.010. Epub 2016 May 14. Review.

30.

Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.

Shrestha N, Araújo F, Shahbazi MA, Mäkilä E, Gomes MJ, Airavaara M, Kauppinen EI, Raula J, Salonen J, Hirvonen J, Sarmento B, Santos HA.

J Control Release. 2016 Jun 28;232:113-9. doi: 10.1016/j.jconrel.2016.04.024. Epub 2016 Apr 16.

PMID:
27091697
31.

Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.

Penttinen AM, Suleymanova I, Albert K, Anttila J, Voutilainen MH, Airavaara M.

J Neurosci Res. 2016 Apr;94(4):318-28. doi: 10.1002/jnr.23708. Epub 2016 Jan 13.

PMID:
26762168
32.

Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity.

Mätlik K, Yu LY, Eesmaa A, Hellman M, Lindholm P, Peränen J, Galli E, Anttila J, Saarma M, Permi P, Airavaara M, Arumäe U.

Cell Death Dis. 2015 Dec 31;6:e2032. doi: 10.1038/cddis.2015.371.

33.

Differentiation and molecular heterogeneity of inhibitory and excitatory neurons associated with midbrain dopaminergic nuclei.

Lahti L, Haugas M, Tikker L, Airavaara M, Voutilainen MH, Anttila J, Kumar S, Inkinen C, Salminen M, Partanen J.

Development. 2016 Feb 1;143(3):516-29. doi: 10.1242/dev.129957. Epub 2015 Dec 30.

34.

Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.

Voutilainen MH, Arumäe U, Airavaara M, Saarma M.

FEBS Lett. 2015 Dec 21;589(24 Pt A):3739-48. doi: 10.1016/j.febslet.2015.09.031. Epub 2015 Oct 9. Review.

35.

Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.

Domanskyi A, Saarma M, Airavaara M.

Hum Gene Ther. 2015 Aug;26(8):550-9. doi: 10.1089/hum.2015.065. Review.

PMID:
26176331
36.

AAV-mediated targeting of gene expression to the peri-infarct region in rat cortical stroke model.

Mätlik K, Abo-Ramadan U, Harvey BK, Arumäe U, Airavaara M.

J Neurosci Methods. 2014 Oct 30;236:107-13. doi: 10.1016/j.jneumeth.2014.08.014. Epub 2014 Aug 23.

37.

Short-term preoperative dietary restriction is neuroprotective in a rat focal stroke model.

Varendi K, Airavaara M, Anttila J, Vose S, Planken A, Saarma M, Mitchell JR, Andressoo JO.

PLoS One. 2014 Apr 4;9(4):e93911. doi: 10.1371/journal.pone.0093911. eCollection 2014.

38.

Local administration of AAV-BDNF to subventricular zone induces functional recovery in stroke rats.

Yu SJ, Tseng KY, Shen H, Harvey BK, Airavaara M, Wang Y.

PLoS One. 2013 Dec 2;8(12):e81750. doi: 10.1371/journal.pone.0081750. eCollection 2013.

39.

Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion and cell surface binding are modulated by KDEL receptors.

Henderson MJ, Richie CT, Airavaara M, Wang Y, Harvey BK.

J Biol Chem. 2013 Feb 8;288(6):4209-25. doi: 10.1074/jbc.M112.400648. Epub 2012 Dec 19.

40.

Neurorestoration.

Airavaara M, Voutilainen MH, Wang Y, Hoffer B.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S143-6. doi: 10.1016/S1353-8020(11)70045-1. Review.

41.

Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Yu SJ, Airavaara M, Shen H, Chou J, Harvey BK, Wang Y.

Psychopharmacology (Berl). 2012 Jun;221(3):479-92. doi: 10.1007/s00213-011-2595-7. Epub 2011 Dec 13.

42.

Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.

Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR.

J Biol Chem. 2011 Dec 30;286(52):45093-102. doi: 10.1074/jbc.M111.310250. Epub 2011 Nov 11.

43.

CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B, Wang Y.

Cell Transplant. 2012;21(6):1213-23. doi: 10.3727/096368911X600948. Epub 2011 Sep 22.

44.

WITHDRAWN: Neurorestoration.

Airavaara M, Voutilainen MH, Wang Y, Hoffer B.

Parkinsonism Relat Disord. 2011 Sep 15. [Epub ahead of print]

PMID:
21924941
45.

Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke.

Harvey BK, Airavaara M, Hinzman J, Wires EM, Chiocco MJ, Howard DB, Shen H, Gerhardt G, Hoffer BJ, Wang Y.

PLoS One. 2011;6(8):e22135. doi: 10.1371/journal.pone.0022135. Epub 2011 Aug 10.

46.

Neurobiology of the incubation of drug craving.

Pickens CL, Airavaara M, Theberge F, Fanous S, Hope BT, Shaham Y.

Trends Neurosci. 2011 Aug;34(8):411-20. doi: 10.1016/j.tins.2011.06.001. Epub 2011 Jul 20. Review.

47.

Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin craving.

Airavaara M, Pickens CL, Stern AL, Wihbey KA, Harvey BK, Bossert JM, Liu QR, Hoffer BJ, Shaham Y.

Addict Biol. 2011 Apr;16(2):261-72. doi: 10.1111/j.1369-1600.2010.00281.x. Epub 2010 Dec 23.

48.

Transgenic animal models of neurodegeneration based on human genetic studies.

Harvey BK, Richie CT, Hoffer BJ, Airavaara M.

J Neural Transm (Vienna). 2011 Jan;118(1):27-45. doi: 10.1007/s00702-010-0476-6. Epub 2010 Oct 8. Review.

49.

Widespread cortical expression of MANF by AAV serotype 7: localization and protection against ischemic brain injury.

Airavaara M, Chiocco MJ, Howard DB, Zuchowski KL, Peränen J, Liu C, Fang S, Hoffer BJ, Wang Y, Harvey BK.

Exp Neurol. 2010 Sep;225(1):104-13. doi: 10.1016/j.expneurol.2010.05.020. Epub 2010 Jun 2.

50.

Role of BDNF and GDNF in drug reward and relapse: a review.

Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L.

Neurosci Biobehav Rev. 2010 Nov;35(2):157-71. doi: 10.1016/j.neubiorev.2009.11.009. Epub 2009 Nov 13. Review.

Supplemental Content

Loading ...
Support Center